Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday.
Highlights Strength of Platform and Track Record of Execution and Value Creation
BANNOCKBURN, Ill., June 26, 2023 /PRNewswire/ -- Option Care Health, Inc. ("Option Care Health" or the
On June 26, 2023, Amedisys, Inc., a Delaware corporation ("Amedisys"), UnitedHealth Group Incorporated, a Delaware corporation ("UnitedHealth Group") and Aurora Holdings Merger Sub Inc., a